| Indication for testing |
Females Tested(n,% , with 95% CI) |
Female Positive Results(n, %, with 95% CI) |
Males Tested(n, %, with 95% CI) |
Male Positive Results(n,% , with 95% CI) |
Total Positive Cases(n,% , with 95% CI) |
Female/Male
Testing Ratio |
Corrected*Female/Male
Testing Ratio |
| Contact Tracing |
1(0.5%, 0.02-2.44) |
1(100%, 5-100) |
17(8.5%, 5.2-13) |
8(57.1%, 24.78-70.27) |
9(50%, 27.81-72.19) |
0.06 |
0.16 |
| Routine Screening |
79(39.5%, 32.9-46.4) |
2(2.5%, 0.43-8.11) |
90(45%, 38.2-51.94) |
0(0%, 0-3.27) |
2(1.18%, 0.2-3.85) |
0.88 |
2.45 |
| High Risk for STI |
30(15%, 10.55-20.46) |
5(16.7%, 6.37-33.15) |
8(4%, 1.88-7.45) |
0(0%, 0-31.23) |
5(13.16%, 4.99-26.78) |
3.75 |
10.46 |
| AsymptomaticPatient Request |
37(18.5%, 13.57-24.34) |
5(13.5%, 5.12-27.44) |
42(21%, 15.78-27.06) |
3(7.1%, 1.85-18.22) |
8(10.13%, 4.82-18.32) |
0.88 |
2.46 |
| Symptoms |
53(26.5%, 20.73-32.94) |
7(13.2%, 5.96-24.39) |
41(20.5%, 15.33-26.52) |
7(17.1%, 7.79-30.88) |
14(14.89%, 8.74-23.19) |
1.29 |
3.61 |
| Other |
0 |
0 |
2(1%, 0.17-3.26) |
0(0%, 0-77.64) |
0(0%, 0-77.64) |
0 |
0 |
| Total |
200 |
20(10%, 6.39-14.76) |
200 |
18(9%, 5.59-13.59) |
38(9.5%, 6.91-12.68) |
1 |
2.79 |
|
